FIRST-TIME-IN-HUMAN DOSE SELECTION - ALLOMETRIC THOUGHTS AND PERSPECTIVES

被引:109
作者
BOXENBAUM, H [1 ]
DILEA, C [1 ]
机构
[1] WYETH AYERST RES,PHILADELPHIA,PA 19101
关键词
D O I
10.1002/j.1552-4604.1995.tb04011.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Some of the many factors that influence dose selection in first-time-in-human studies are examined. These include animal toxicology, toxicokinetics, allometric scaling, pharmacokinetics, body surface area correlations, and integration of preclinical pharmacologic and toxicologic data. Appropriate preclinical evaluation and analysis may reduce the frequency and severity of unexpected toxic events arising during single-dose, phase I testing. However, significant intrinsic uncertainties in this process presently exist and will continue to exist well into the foreseeable future. With our present state of knowledge, we cannot provide a realistic and reasonable algorithm for ascertaining first-time-in-human doses: any decision tree would be too unwieldy. There are several rules of thumb that do have a place in the evaluation and decision-making process, however.
引用
收藏
页码:957 / 966
页数:10
相关论文
共 36 条
[1]   INCORPORATION OF NEW SCIENCE INTO RISK ASSESSMENT [J].
ABELSON, PH .
SCIENCE, 1990, 250 (4987) :1497-1497
[2]  
[Anonymous], 1928, POSSIBLE WORLDS OTHE
[3]  
[Anonymous], 1959, APPRAISAL SAFETY CHE
[4]  
Boxenbaum H., 1990, ADV DRUG RES, V29, P139
[5]  
Brody S, 1945, BIOENERGETICS GROWTH, P1
[6]  
Calder WA., 1984, SIZE FUNCTION LIFE H
[7]   THE CURRENT STATUS OF ATTEMPTS TO PREDICT SPECIES-DIFFERENCES IN DRUG-METABOLISM [J].
CALDWELL, J .
DRUG METABOLISM REVIEWS, 1981, 12 (02) :221-237
[8]  
CHAPPELL WR, 1991, ADV DRUG RES, V20, P1
[9]  
COLLINS JM, 1986, CANCER TREAT REP, V70, P73
[10]   PROBLEMS OF ONTOGENY AND PHYLOGENY IN BRAIN-SIZE EVOLUTION [J].
DEACON, TW .
INTERNATIONAL JOURNAL OF PRIMATOLOGY, 1990, 11 (03) :237-282